Delivering answers to patients, sooner

Accelerating Breakthrough Discoveries That Transform Medicine

Pangea Laboratory partners with clinicians, researchers, pharma, and diagnostic developers to bring tests to market that deliver accuracy, speed, and reliability.

Integrated NGS Services Across the Development Spectrum

Pangea is more than a sequencing provider: we’re your partner in advancing healthcare. Our CLIA-certified and CAP-accredited laboratory combines deep scientific expertise, advanced bioinformatics, and scalable infrastructure to help clinicians diagnose with confidence, researchers accelerate discovery, and developers bring breakthrough diagnostics to market.

Pangea's Services

Whether you’re validating a novel biomarker, launching a diagnostic test, or seeking precision clinical insights, our integrated NGS capabilities accelerate your path from research to patient impact.

Clinical Development

Transform innovative research into validated, clinically actionable insights through validated NGS-based diagnostics and precision testing, all within a CLIA/CAP environment.

Reference Lab Services

Empower researchers and clinicians with high-throughput, high-quality sequencing and analysis backed by rigorous quality controls and reproducible standards.

Diagnostic Laboratory

Explore our menu of non-invasive diagnostic testing options that enable earlier detection and improved patient outcomes across oncology and infectious disease assays. 

Concept to Commercialization

Pangea is Your
End-to-End Partner

From early-stage feasibility with R&D support to clinical validation and market launch, Pangea Laboratory provides a complete continuum of sequencing, analysis, ongoing quality assessment, and regulatory support. Our approach ensures every phase, from sample collection to bioinformatics reporting, meets the highest standards of accuracy and compliance with scalability. 

1

Ideation

2

Development

3

Validation

4

Commercialization

Accredited for Quality. Trusted for Results.

Pangea Laboratory operates under CLIA certification and CAP accreditation, ensuring precision, consistency, and regulatory compliance across all services. These accreditations reflect our commitment to maintaining the highest standards of analytical performance and patient safety in every test we deliver.

Our Offerings

Custom Sequencing Solutions

Tailored assays and bioinformatics pipelines for R&D and clinical translation.

Bladder CARE™

Urine-based accurate bladder cancer testing made simple.

iFOB

Fecal Occult Blood testing for the early detection of colorectal cancer.

PrecisionBIOME™

Bacterial and fungal identification for clinical and industrial applications.

Coming Soon | Q2 2026

Latest News + Insights

Explore how Pangea Laboratory is shaping the future of precision diagnostics, from NGS innovations to clinical assay development.

Partners

Genetic Analysis AS and Pangea Laboratory LLC announces the launch of GA-map® MHI GutHealth in the USA

The GA-map® MHI GutHealth is the first microbiome-based diagnostic test providing clinically actionable insights into antibiotic-induced microbiome imbalances. The test has been developed by GA in collaboration…

Pangea in the News

Pangea Laboratory Appoints John Moore as Chief Executive Officer

Partnerships

Pangea Laboratory Partners with Unilabs to Introduce Bladder CARE™ Assay…

Research

Pangea Laboratory Receives FDA Breakthrough Device Designation for the Bladder CARE™ Assay

The Bladder CARE™ Assay measures the methylation levels of three urothelial cancer-specific DNA biomarkers in a single qPCR reaction. It markedly outperforms traditional cytology…

Scroll to Top

Custom Sequencing Solutions

Have questions? Contact us for more details.

PrecisionBIOME™

A targeted NGS platform developed for the comprehensive detection and characterization of bacterial and fungal pathogens, viral agents (HSV/HPV), and sexually transmitted infections (STIs), alongside the molecular profiling of antimicrobial resistance (AMR) markers for clinical diagnostics in vaginal and uterine specimens – Coming in Q2 2026.

Have questions? Contact us for more details.